Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 4/2017

Content (12 Articles)

Open Access Original Article

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer

Renate Pichler, Georg Gruenbacher, Zoran Culig, Andrea Brunner, Dietmar Fuchs, Josef Fritz, Hubert Gander, Andrea Rahm, Martin Thurnher

Original Article

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study

Benjamin Weide, Alexander Martens, Kilian Wistuba-Hamprecht, Henning Zelba, Ludwig Maier, Hans-Peter Lipp, Bernhard D. Klumpp, Daniel Soffel, Thomas K. Eigentler, Claus Garbe

Original Article

The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients

Ana Colado, María Belén Almejún, Enrique Podaza, Denise Risnik, Carmen Stanganelli, Esteban Enrique Elías, Patricia Dos Santos, Irma Slavutsky, Horacio Fernández Grecco, María Cabrejo, Raimundo Fernando Bezares, Mirta Giordano, Romina Gamberale, Mercedes Borge

Original Article

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

Cheng Chen, Kesang Li, Hua Jiang, Fei Song, Huiping Gao, Xiaorong Pan, Bizhi Shi, Yanyu Bi, Huamao Wang, Hongyang Wang, Zonghai Li

Original Article

Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients

Kimberly R. Jordan, Puja Kapoor, Eric Spongberg, Richard P. Tobin, Dexiang Gao, Virginia F. Borges, Martin D. McCarter

Original Article

Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients: a pilot study

Kirsten A. Ward-Hartstonge, John L. McCall, Timothy R. McCulloch, Ann-Kristin Kamps, Adam Girardin, Erika Cretney, Fran M. Munro, Roslyn A. Kemp

Original Article

Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α

Genevieve Hartley, Daniel Regan, Amanda Guth, Steven Dow

Original Article

Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D

Zhongjuan Wang, Linghua Guo, Yuan Song, Yinsheng Zhang, Dandan Lin, Bo Hu, Yu Mei, Dedy Sandikin, Haiyan Liu

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine